Summary of Solventum's Q2 2026 Earnings Call

1Key Financial Results and Metrics

Sales: $2.2 billion, up 9.5% organically year-over-year; 2.2% reported growth.

Earnings Per Share (EPS): $2.55, including a $0.34 contribution from advanced orders and a $0.48 benefit from tariff refunds. Excluding these, EPS would have been $1.73.

Gross Margin: 60.1%, boosted by a one-time tariff refund of $100 million; adjusted gross margins were approximately 55.6%.

Operating Income: $627 million, with an operating margin of 28.4%. Adjusted for advanced orders and tariff refunds, the operating margin would be around 21.7%.

Free Cash Flow: Generated $144 million in the quarter, with expectations for improvement as separation-related costs decline.

Share Repurchase: Nearly 4 million shares repurchased for $288 million, totaling 4.8 million shares for $355 million year-to-date.

2Strategic Updates and Business Highlights

Transformation Progress: Nearing completion of separation from 3M, with 70% of transition service agreements exited and significant ERP cutover progress.

Health Information Systems (HIS) Separation: Announced plans to separate HIS to maximize value and focus on MedTech core businesses (MedSurg and Dental).

Acquisition Performance: Acera, acquired previously, showed strong growth of 48%, contributing $32 million in sales.

Innovation Pipeline: Expecting to launch nearly 20 new products by Q1 2028, focusing on growth drivers in MedSurg, Dental, and HIS.

3Forward Guidance and Outlook

2026 Organic Sales Growth: Tightened guidance to 2.5% to 3%, adjusting for SKU exits, indicating a normalized growth range of 3.5% to 4%.

Operating Margin Guidance: Increased to a range of 22.2% to 22.7%, reflecting tariff refund benefits.

EPS Guidance: Raised to $7.10 to $7.20, up from $6.40 to $6.60.

Free Cash Flow Outlook: Estimated to be in the range of $200 million to $300 million, with most expected in Q4.

4Bad News, Challenges, or Points of Concern

Advanced Orders Impact: $125 million in advanced orders will reverse in Q3, expected to negatively impact sales growth and EPS by approximately $0.34.

Tariff Refunds: While beneficial this quarter, the tariff refund is a one-time event and not expected to recur in the second half.

Separation Costs: Ongoing separation-related activities are creating temporary demands on cash flow, with some costs expected to persist into 2027.

Market Utilization Trends: Mixed signals regarding patient volumes and procedure demand, with management not currently seeing softness but acknowledging external noise.

5Notable Q&A Insights

HIS Separation Rationale: Management believes HIS can unlock greater value as a standalone entity or combined with a larger player in the healthcare IT space, despite its current strong performance.

Market Health: Management reports no current softness in demand across segments, maintaining confidence in the business environment.

Capital Allocation Post-HIS: Proceeds from the HIS separation will likely be used for shareholder returns, with a focus on maintaining a balanced capital allocation strategy.

Integration of Acera: Management is optimistic about Acera's continued double-digit growth and its integration into the broader portfolio. Overall, Solventum's Q2 2026 results reflect strong operational execution and strategic progress, despite some anticipated challenges in the upcoming quarters due to advanced order reversals and ongoing separation costs.